Dorval Receives Second Shipment of Clones – Revised

- February 21st, 2019

Matica Enterprises Inc. (CSE:MMJ) (Frankfurt:39N) (OTC:MQPXF) (“Matica” or the “Company”) is pleased to announce that the Dorval growing facility has received its second shipment of rooted starting materials.

Matica Enterprises Inc. (CSE:MMJ) (Frankfurt:39N) (OTC:MQPXF) (“Matica” or the “Company”) is pleased to announce that the Dorval growing facility has received its second shipment of rooted starting materials. 500 clones of Sensi Star arrived today from THC BioMed. This is our second shipment from THC BioMed. The first clones arrived in January (NR, Jan. 23, 2019) and have been in the vegetation room since February 6th.

About Matica

Matica is a multi-faceted, innovative company in the Quebec cannabis space. RoyalMax Biotechnology Canada Inc. (“RoyalMax”) was recently granted a cultivation licence by Health Canada for the production facility in Dorval, Quebec. RoyalMax is one of only 11 Licensed Producers in the Province of Quebec. Matica intends to build 1,000,000 square feet of greenhouses on a 181 acre property in the township of Hemmingford, south of Montreal. Matica has entered into an agreement with Yunify Natural Technologies, a Quebec based health and personal care research and innovation company.

For more information on Matica Enterprises please visit the website at: www.maticaenterprises.com.

On behalf of the Board of Directors

MATICA ENTERPRISES INC.

Boris Ziger

Boris Ziger, CEO & Chairman

The Company’s public filings are available for review at www.sedar.com and www.thecse.com.

For further information, please contact Boris Ziger, at:

Telephone: 416-304-9935

E-mail: info@maticaenterprises.com

Website: www.maticaenterprises.com

Disclaimer for Forward-Looking Information

Certain information in this press release may constitute forward-looking information. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Corporation assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to the Corporation. Additional information identifying risks and uncertainties is contained in the Corporation’s filings with the Canadian securities regulators, which filings are available at www.sedar.com.

This news release contains statements about the Company’s information that may be made available on the S&P Capital IQ Corporation Records Listing Program and the business of Matica that are forward-looking in nature and as a result, are subject to certain risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from the forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. We seek Safe Harbor.

Suite 1102 – 44 Victoria Street

Toronto, ON, M5C 1Y2

Tel: (416) 304-9935

Website: www.maticaenterprises.com

Click here to connect with Matica Enterprises Inc. (CSE:MMJ; FWB:39N; OTC:MQPXF) for an Investor Presentation.

Get the latest Cannabis Investing stock information

Get the latest information about companies associated with Cannabis Investing Delivered directly to your inbox.

Cannabis Investing

Select All
Select None

One response to “Dorval Receives Second Shipment of Clones – Revised

Leave a Reply

Your email address will not be published. Required fields are marked *